Cargando…
Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion
There is increasing interest to administer ibuprofen as a continuous infusion instead of a traditional bolus for treating Patent Ductus Arteriosus (PDA). However, its compatibility data with commonly used drugs in the neonatal period, including parenteral nutrition (PN) and lipids is unavailable. Th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752020/ https://www.ncbi.nlm.nih.gov/pubmed/29298359 http://dx.doi.org/10.1371/journal.pone.0190577 |
_version_ | 1783290063316058112 |
---|---|
author | Garcia, Jowell Garg, Alka Song, Yunmei Fotios, Ambados Andersen, Chad Garg, Sanjay |
author_facet | Garcia, Jowell Garg, Alka Song, Yunmei Fotios, Ambados Andersen, Chad Garg, Sanjay |
author_sort | Garcia, Jowell |
collection | PubMed |
description | There is increasing interest to administer ibuprofen as a continuous infusion instead of a traditional bolus for treating Patent Ductus Arteriosus (PDA). However, its compatibility data with commonly used drugs in the neonatal period, including parenteral nutrition (PN) and lipids is unavailable. The aim is to determine the compatibility of intravenous ibuprofen lysine with various ANZNN parenteral nutrition consensus group standard neonatal PN formulations and lipids. The PN and lipid solutions used in a tertiary neonatal unit were obtained. These included a Starter, Standard Preterm and low carbohydrate PN, and IV SMOF lipid admixture (SMOFLipid 20% 15 mL; Vitalipid N infant 4 mL, Soluvit N 1 mL) plus vitamin mixtures. 10% glucose was used as a control. 1:1 mixtures of different concentrations (1.25 to 5mg/mL) of ibuprofen lysine and each of the PN/glucose/lipid formulations were made. Samples were taken at hourly intervals for a total of 4 hours and tested for both physical (visual assessment, pH and microscopy) and chemical compatibility (High Performance Liquid Chromatography analysis). Zeta potential and particle diameter were measured for SMOF lipid admixture and ibuprofen combination to assess emulsion stability. 24 hour stability of ibuprofen dilution in 5 mL BD Luer-lok polypropylene syringes at 25°C was also assessed. Most PN formed opaque solutions when mixed with ibuprofen 2.5 and 5mg/mL solutions. However, ibuprofen dilution of 1.25mg/mL produced clear, colourless solutions with no microscopic particles when mixed with all PN/glucose/lipid formulations tested. Ibuprofen was chemically stable with all PN and SMOF lipid admixture, for a period of 4 hours. The zeta potential and particle diameter were within acceptable limits. Ibuprofen lysine was stable over 24 hours in Luer-lok polypropylene syringes. Ibuprofen 1.25mg/mL is physically and chemically compatible with 10% glucose, starter PN, standard preterm and low carbohydrate PN, and SMOF lipid admixture plus vitamins for a period of four hours, which is the maximum time they could be in an admixture during a continuous infusion. |
format | Online Article Text |
id | pubmed-5752020 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-57520202018-01-09 Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion Garcia, Jowell Garg, Alka Song, Yunmei Fotios, Ambados Andersen, Chad Garg, Sanjay PLoS One Research Article There is increasing interest to administer ibuprofen as a continuous infusion instead of a traditional bolus for treating Patent Ductus Arteriosus (PDA). However, its compatibility data with commonly used drugs in the neonatal period, including parenteral nutrition (PN) and lipids is unavailable. The aim is to determine the compatibility of intravenous ibuprofen lysine with various ANZNN parenteral nutrition consensus group standard neonatal PN formulations and lipids. The PN and lipid solutions used in a tertiary neonatal unit were obtained. These included a Starter, Standard Preterm and low carbohydrate PN, and IV SMOF lipid admixture (SMOFLipid 20% 15 mL; Vitalipid N infant 4 mL, Soluvit N 1 mL) plus vitamin mixtures. 10% glucose was used as a control. 1:1 mixtures of different concentrations (1.25 to 5mg/mL) of ibuprofen lysine and each of the PN/glucose/lipid formulations were made. Samples were taken at hourly intervals for a total of 4 hours and tested for both physical (visual assessment, pH and microscopy) and chemical compatibility (High Performance Liquid Chromatography analysis). Zeta potential and particle diameter were measured for SMOF lipid admixture and ibuprofen combination to assess emulsion stability. 24 hour stability of ibuprofen dilution in 5 mL BD Luer-lok polypropylene syringes at 25°C was also assessed. Most PN formed opaque solutions when mixed with ibuprofen 2.5 and 5mg/mL solutions. However, ibuprofen dilution of 1.25mg/mL produced clear, colourless solutions with no microscopic particles when mixed with all PN/glucose/lipid formulations tested. Ibuprofen was chemically stable with all PN and SMOF lipid admixture, for a period of 4 hours. The zeta potential and particle diameter were within acceptable limits. Ibuprofen lysine was stable over 24 hours in Luer-lok polypropylene syringes. Ibuprofen 1.25mg/mL is physically and chemically compatible with 10% glucose, starter PN, standard preterm and low carbohydrate PN, and SMOF lipid admixture plus vitamins for a period of four hours, which is the maximum time they could be in an admixture during a continuous infusion. Public Library of Science 2018-01-03 /pmc/articles/PMC5752020/ /pubmed/29298359 http://dx.doi.org/10.1371/journal.pone.0190577 Text en © 2018 Garcia et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Garcia, Jowell Garg, Alka Song, Yunmei Fotios, Ambados Andersen, Chad Garg, Sanjay Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion |
title | Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion |
title_full | Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion |
title_fullStr | Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion |
title_full_unstemmed | Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion |
title_short | Compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion |
title_sort | compatibility of intravenous ibuprofen with lipids and parenteral nutrition, for use as a continuous infusion |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752020/ https://www.ncbi.nlm.nih.gov/pubmed/29298359 http://dx.doi.org/10.1371/journal.pone.0190577 |
work_keys_str_mv | AT garciajowell compatibilityofintravenousibuprofenwithlipidsandparenteralnutritionforuseasacontinuousinfusion AT gargalka compatibilityofintravenousibuprofenwithlipidsandparenteralnutritionforuseasacontinuousinfusion AT songyunmei compatibilityofintravenousibuprofenwithlipidsandparenteralnutritionforuseasacontinuousinfusion AT fotiosambados compatibilityofintravenousibuprofenwithlipidsandparenteralnutritionforuseasacontinuousinfusion AT andersenchad compatibilityofintravenousibuprofenwithlipidsandparenteralnutritionforuseasacontinuousinfusion AT gargsanjay compatibilityofintravenousibuprofenwithlipidsandparenteralnutritionforuseasacontinuousinfusion |